The detection of antibody against active site of botulinum toxin A and complexing protein before and after using botulinum toxin

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220214001

Enrollment

120

Registered

2022-02-14

Start date

2021-10-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy human volunteers Botulinum Toxins, Antibody

Interventions

Draw the blood 10ml from the participants who have been injected with botulinum toxin for more than 6 month. Blood sample will be centrifuged to get the plasma. Evaluate the level of antibody against

Experimental Other

ELISA test to evaluate the antibody against complexing protein of botulinum toxin

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy male or female volunteers age 18-60 years 2. No history of botulinum toxin treatment failure 3. No history of immunodeficiency disease or taking any immunosuppressive drug

Exclusion criteria

Exclusion criteria: 1. pregnant or lactating woman 2. Was treated with botulinum toxin during 6 months prior

Design outcomes

Primary

Measure	Time frame
Percentage of antibody against complexing protein day 0 Percentage of antibody against complexing protein	—

Secondary

Measure	Time frame
Level of hIgG against complexing protein day 0 nano grams of hIgG against complexing protein	—

Countries

Thailand

Contacts

Public ContactSurachet Sirisuthivoranunt

Faculty of Medicine Siriraj Hospital, Mahidol University

siri.surachet@gmail.com024199933

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026